Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors
Hao Lei(Xi'an Jiaotong University), San‐Qi Zhang(Xi'an Jiaotong University), Junjie Zhang(Chemical Synthesis Lab), Hao Zhang(Qingdao University), Yanjie Liu(Tongji University), Shu Fan(Xi'an Jiaotong University), Minhang Xin(Zhejiang University), Aqun Zheng(Xi'an Jiaotong University), Yuan‐Yuan Hei(Xi'an Jiaotong University)
Cited by 67
Related Papers
Small molecule selenium-containing compounds: Recent development and therapeutic applications
|European Journal of Medicinal Chemistry|2021|233
Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y
|European Journal of Medicinal Chemistry|2019|192
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
|European Journal of Medicinal Chemistry|2018|168
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
|European Journal of Medicinal Chemistry|2020|120
Strategies to target the Hedgehog signaling pathway for cancer therapy
|Medicinal Research Reviews|2018|108